Clinical Research Directory
Browse clinical research sites, groups, and studies.
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
Sponsor: University of Chicago
Summary
The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.
Official title: TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)
Key Details
Gender
FEMALE
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
85
Start Date
2025-03-18
Completion Date
2032-06
Last Updated
2026-02-17
Healthy Volunteers
No
Conditions
Interventions
Cyclophosphamide
Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.
Epirubicin
Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.
Docetaxel
Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.
Carboplatin
Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.
Breast Surgery
Participants will undergo breast surgery after completing dosing with Carboplatin and Docetaxel to remove any remaining cancer in the breast.
Capecitabine
Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.
Locations (4)
Lagos State University Teaching Hospital
Ikeja, Lagos, Nigeria
Lagos University Teaching Hospital
Yaba, Lagos, Nigeria
Obafemi Awolowo University Teaching Hospitals Complex
Ile-Ife, Osun State, Nigeria
University of Ibadan Hospital
Ibadan, Oyo State, Nigeria